Dual mRNA nanoparticles strategy for enhanced pancreatic cancer treatment and β-elemene combination therapy

Area of Science:

• Oncology
• Immunology
• Nanotechnology
• Biotechnology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) exhibits significant immune resistance, limiting single-agent immunotherapy efficacy.
• Conventional immune checkpoint inhibitors combined with neoantigen vaccines show promise but face challenges like T cell exhaustion and systemic toxicity.
• Novel therapeutic strategies are crucial to overcome these limitations in PDAC treatment.

Purpose of the Study:

• To investigate the efficacy of mRNA polymeric nanoparticles encoding anti-PD-1 antibodies for in situ antibody production at the tumor site.
• To evaluate this approach as a multimodal immunotherapy combination with neoantigen-based mRNA vaccines for PDAC.
• To assess the potential of reducing systemic toxicities associated with conventional checkpoint inhibition.

Main Methods:

• Development of mRNA polymeric nanoparticles for in situ production of anti-PD-1 antibodies.
• Combination therapy utilizing these nanoparticles with a neoantigen-based mRNA vaccine.
• Evaluation of therapeutic efficacy and immune responses in preclinical models of PDAC.

Main Results:

• In situ production of anti-PD-1 antibodies via mRNA nanoparticles significantly enhanced the therapeutic efficacy of neoantigen mRNA vaccines.
• This strategy protected tumor-infiltrating T cells from PD-1 mediated inhibition.
• The localized antibody production potentially reduced systemic toxicities compared to traditional methods.

Conclusions:

• A dual mRNA nanoparticle strategy offers an innovative approach for effective tumor neoantigen immunotherapy in PDAC.
• This mRNA-based in situ antibody production method represents a promising combination therapy for pancreatic cancer.
• The strategy may be compatible with other clinically approved drugs, expanding combination therapy options.